Prognostic significance of serum albumin in patients with metastatic renal cell carcinoma

Medical Oncology

Volumn 31, Issue 3, 2014, Pages

  Stenman, Maria ^a,b,c   Laurell, Anna ^a   Lindskog, Magnus ^a,b  

^a UPPSALA UNIVERSITY   (Sweden)

^b KAROLINSKA INSTITUTE   (Sweden)

^c UPPSALA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Albumin; Inflammation; Metastatic; Prognostic factor; Renal cell carcinoma; Weight loss

Indexed keywords

BEVACIZUMAB; C REACTIVE PROTEIN; INTERFERON; PAZOPANIB; SERUM ALBUMIN; SORAFENIB; SUNITINIB; TUMOR MARKER;

ADULT; AGED; ALBUMIN BLOOD LEVEL; ANTIANGIOGENIC THERAPY; ARTICLE; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; FEMALE; HUMAN; KIDNEY METASTASIS; MAJOR CLINICAL STUDY; MALE; METASTASIS RESECTION; MOLECULARLY TARGETED THERAPY; NEPHRECTOMY; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN BLOOD LEVEL; RETROSPECTIVE STUDY; SELF REPORT; SURVIVAL TIME; THROMBOCYTE COUNT; VERY ELDERLY; WEIGHT REDUCTION; CANCER STAGING; FOLLOW UP; KIDNEY CARCINOMA; KIDNEY TUMOR; METABOLISM; METASTASIS; MIDDLE AGED; MORTALITY; PAPILLARY CARCINOMA; PATHOLOGY; PROGNOSIS; SURVIVAL RATE;

ADULT; AGED; AGED, 80 AND OVER; C-REACTIVE PROTEIN; CARCINOMA, PAPILLARY; CARCINOMA, RENAL CELL; FEMALE; FOLLOW-UP STUDIES; HUMANS; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASM STAGING; PROGNOSIS; SERUM ALBUMIN; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL;

EID: 84892931076     PISSN: 13570560     EISSN: 1559131X     Source Type: Journal    
DOI: 10.1007/s12032-014-0841-7     Document Type: Article

References (21)

1. Wahlgren T, Harmenberg U, Sandström P, Lundstam S, Kowalski J, Jakobsson M, et al. Treatment and overall survival in renal cell carcinoma: a Swedish population-based study (2000-2008). Br J Cancer. 2013;108(7):1541-9.
2. Escudier B, Albiges L, Massard C, Loriot Y, Fizazi K. How to select amongst available options for the treatment of advanced RCC? Ann Oncol. 2012;23(Suppl 10):309-12.
3. Motzer RJ, Bacik J, Murphy BA, Russo P, Mazumdar M. Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J Clin Oncol. 2002;20(1):289-96.
4. Allavena P, Sica A, Solinas G, Porta C, Mantovani A. The inflammatory micro-environment in tumor progression: the role of tumor-associated macrophages. Crit Rev Oncol Hematol. 2008;66(1):1-9.
5. Heng DYC, Xie W, Regan MM, Warren MA, Golshayan AR, Sahi C, et al. Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study. J Clin Oncol. 2009;27(34):5794-9.
6. Heng DYC, Xie W, Regan MM, Harshman LC, Bjarnason GA, Vaishampayan UN, et al. External validation and comparison with other models of the International metastatic renal-cell carcinoma database consortium prognostic model: a population-based study. Lancet Oncol. 2013;14(2):141-8.
7. Beuselinck B, Vano Y-A, Oudard S, Wolter P, De Smet R, Depoorter L, et al. Prognostic impact of baseline serum C-reactive protein in metastatic renal cell carcinoma patients treated with sunitinib. BJU Int 2013, Epub.
8. Kwon W-A, Cho I-C, Yu A, Nam B-H, Joung JY, Seo HK, et al. Validation of the MSKCC and heng risk criteria models for predicting survival in patients with metastatic renal cell carcinoma treated with sunitinib. Ann Surg Oncol. 2013;20(13):4397-404.
9. Karakiewicz PI, Sun M, Bellmunt J, Sneller V, Escudier B. Prediction of progression-free survival rates after bevacizumab plus interferon versus interferon alone in patients with metastatic renal cell carcinoma: comparison of a nomogram to the Motzer criteria. Eur Urol. 2011;60(1):48-56.
10. Yildiz I, Sen F, Kilic L, Ekenel M, Ordu C, Kilicaslan I, et al. Prognostic factors associated with the response to sunitinib in patients with metastatic renal cell carcinoma. Curr Oncol. 2013;20(6):e546-53.
11. Ramsey S, Lamb GWA, Aitchison M, Graham J, McMillan DC. Evaluation of an inflammation-based prognostic score in patients with metastatic renal cancer. Cancer. 2007;109(2):205-12.
12. Sufrin G, Mirand EA, Moore RH, Chu TM, Murphy GP. Hormones in renal cancer. J Urol. 1977;117(4):433-8.
13. Kim HL, Belldegrun AS, Freitas DG, Bui MHT, Han K, Dorey FJ, et al. Paraneoplastic signs and symptoms of renal cell carcinoma: implications for prognosis. J Urol. 2003;170(5):1742-6.
14. Fox P, Hudson M, Brown C, Lord S, Gebski V, De Souza P, et al. Markers of systemic inflammation predict survival in patients with advanced renal cell cancer. Br J Cancer. 2013;109(1):147-53.
15. Margulis V, Shariat SF, Rapoport Y, Rink M, Sjoberg DD, Tannir NM, et al. Development of accurate models for individualized prediction of survival after cytoreductive nephrectomy for metastatic renal cell carcinoma. Eur Urol. 2013;63(5):947-52.
16. Motzer RJ, Bukowski RM, Figlin RA, Hutson TE, Michaelson MD, Kim ST, et al. Prognostic nomogram for sunitinib in patients with metastatic renal cell carcinoma. Cancer. 2008;113(7):1552-8.
17. Motzer RJ, Escudier B, Bukowski R, Rini BI, Hutson TE, Barrios CH, et al. Prognostic factors for survival in 1059 patients treated with sunitinib for metastatic renal cell carcinoma. Br J Cancer. 2013;108(12):2470-7.
18. Rini BI, Escudier B, Tomczak P, Kaprin A, Szczylik C, Hutson TE, et al. Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial. Lancet. 2011;378(9807):1931-9.
19. Wallengren O, Lundholm K, Bosaeus I. Diagnostic criteria of cancer cachexia: relation to quality of life, exercise capacity and survival in unselected palliative care patients. Support Care Cancer. 2013;21(6):1569-77.
20. Finke J, Ko J, Rini B, Rayman P, Ireland J, Cohen P. MDSC as a mechanism of tumor escape from sunitinib mediated anti-angiogenic therapy. Int Immunopharmacol. 2011;11(7):856-61.
21. Brecht K, Weigert A, Hu J, Popp R, Fisslthaler B, Korff T, et al. Macrophages programmed by apoptotic cells promote angiogenesis via prostaglandin E2. FASEB J. 2011;25(7):2408-17.